ArticleJournal of cosmetic dermatology2025
Finasteride Use: Evaluation of Depression and Suicide Risk.
Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- No Evidence of Post-Finasteride Syndrome in 267,983 Person-Years Follow-up in the Prostate Cancer Prevention Trial.Urology · 2026Article
- Finasteride, pharmacogenomics, and suicide risk: a public health concern.The pharmacogenomics journal · 2026Review
- Characterization and Management of Androgenetic Alopecia in Transgender and Gender-Diverse Individuals: A Narrative Review.Dermatology and therapy · 2026Review
- 5α-Reductase Isoenzymes: From Neurosteroid Biosynthesis to Neuropsychiatric Outcomes.NeuroSci · 2026Review
- Patient Satisfaction, Side Effects, and Other Reactions Reported by Adult Men Prescribed Compounded Topical Finasteride via a National Telehealth Platform: Retrospective Analysis of Real-World Data.JMIR dermatology · 2026Article
- Finasteride Use Does Not Lead to Depression or Suicide: Insights From a Large-Scale Cohort Study and Mendelian Randomization Analysis.Journal of cosmetic dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral finasteride 1 mg/day is indicated for androgenetic alopecia (AGA), while 5 mg/day is for benign prostatic hyperplasia (BPH). Oral finasteride has been linked with depression and suicide; however, a causal association is uncertain. The so-called post-finasteride syndrome (PFS) refers to a "cluster" of side effects experienced by some men (i.e., cis men) after taking oral finasteride.
aimsThe objective of the current study was to evaluate the association of depression and suicide with oral finasteride in males, using data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS). As a secondary objective, we conducted disproportionality analyses of FAERS data to assess whether oral dutasteride use was linked to psychological symptoms related to depression and suicidality.
methodsWe conducted disproportionality analyses for 5 AEs using MedDRA terms. Associations were metricized with the reporting odds ratio (ROR) across 3 time periods, namely, 2006-2011, 2013-2018, and 2019-2023.
resultsNo significant AEs/signals were detected with oral finasteride from 2006 to 2011 for any of the 5 AEs (completed suicide, depression suicidal, suicidal behavior, suicidal ideation, attempted suicide). Signals were detected for some AEs during 2013-2018 and 2019-2023. For example, there was a greater likelihood of reporting suicidal ideations in individuals taking oral finasteride during 2013-2018 (ROR = 2.8, p < 0.05) and 2019-2023 (ROR = 5.0, p < 0.05). In contrast, no signals were detected with oral dutasteride during 2006-2011, 2013-2018, and 2019-2023.
conclusionThe study found no significant correlation between oral finasteride and depression/suicide reports from 2006 to 2011 but noted a significant number of such reports in 2013-2018 and 2019-2023. This increase may be linked to heightened awareness of AEs following the recognition of so-called PFS in 2012.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.